CRISPR gains license to Anagenesis’ P2MCs technology for cell therapy for muscle diseases
CRISPR Therapeutics and Anagenesis Biotechnologies announced a strategic in-licensing and collaboration agreement, which grants CRISPR Therapeutics exclusive worldwide license to Anagenesis’ Paraxial Mesoderm Multipotent Cells (P2MCs) technology for cell therapy for all human muscle diseases.
Click on this link for more information.
